Agonists at PPAR-γ suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts

British Journal of Pharmacology

Volumn 153, Issue 7, 2008, Pages 1409-1419

  Hao, G H ^a,b   Niu, X L ^a,b   Gao, D F ^a   Wei, J ^a   Wang, N P ^c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

15d PGJ 2; Angiotensin; Cardiac fibroblast; Extracellular matrix; Fibrosis; Plasminogen activator inhibitor 1; PPAR ; Rosiglitazone

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 4,4' ISOPROPYLIDENEDIPHENOL; ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BODY WEIGHT; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; HEART WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ANGIOTENSIN II; ANIMALS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; MALE; MYOCARDIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 41649105085     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.21     Document Type: Article

References (52)

1. Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ et al. (2002). Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat. Pharmacology 66: 26-30.
2. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N et al. (2002). Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105: 1240-1246.
3. Baltatu O, Silva Jr JA, Ganten D, Bader M (2000). The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 35: 409-412.
4. Brown RD, Ambler SK, Mitchell MD, Long CS (2005). The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687.
5. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M et al. (2005). PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288: L1146-L1153.
6. Cao Z, Ye P, Long C, Chen K, Li X, Wang H (2007). Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology 79: 184-192.
7. Chen K, Chen J, Li D, Zhang X, Mehta JL (2004a). Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 44: 655-661.
8. Chen K, Li D, Zhang X, Hermonat PL, Mehta JL (2004b). Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone. J Cardiovasc Pharmacol 44: 682-687.
9. Chintalgattu V, Katwa LC (2004). The modulation of PPAR-gamma expression by angiotensin-II in cardiac myofibroblasts. FASEB J 18; abstract no. 677.8 (http://www.fasebj.org/).
10. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM (1998). Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17: 3091-3100.
11. Díaz-Delfín J, Morales M, Caelles C (2007). Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 56: 1865-1871.
12. Diep QN, EI Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A et al. (2002). Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105: 2296-2302.
13. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
14. Eddy AA (2002). Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209-F220.
15. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A et al. (2000). Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 80: 513-527.
16. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G et al. (2002). Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940.
17. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N et al. (2007). Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol 73: 185-197.
18. Geng DF, Wu W, Jin DM, Wang JF, Wu YM (2006). Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 113: 86-91.
19. Gibbons GH (1998). The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Am J Hypertens 11: 177S-181S.
20. Houseknecht KL, Cole BM, Steele PJ (2002). Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22: 1-23.
21. Hsueh WA, Bruemmer D (2004). Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43: 297-305.
22. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN et al. (2003). Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42: 737-743.
23. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE (2001). Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104: 839-844.
24. Karin M (1995). The regulation of AP-1 binding activity by mitogenactivated protein kinase. J Biol Chem 270: 16483-16486.
25. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W et al. (1999). Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 258: 431-435.
26. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE et al. (2000). Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101: 1130-1137.
27. Kermani A, Garg A (2003). Thiazolidinedione-associated congestive heart failure and pulmonary oedema. Mayo Clin Proc 78: 1088-1091.
28. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A (2002). Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51: 1507-1514.
29. Kim NN, Villarreal FJ, Printz MP, Lee AA, Dillmann WH (1995a). Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am J Physiol 269: E426-E437.
30. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H (1995b). Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25: 1252-1259.
31. Kudoh S, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiojima IX et al. (1997). Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 80: 139-146.
32. Makino N, Sugano M, Satoh S, Oyama J, Maeda T (2006). Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. Cell Biochem Biophys 44: 65-71.
33. Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T (2002). Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells. J Biol Chem 277: 141-147.
34. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB (2000). Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58: 251-259.
35. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA (2001). Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 37: 722-727.
36. Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
37. Omura T, Yoshiyama M, Matsumoto R, Kusuyama T, Enomoto S, Nishiya D et al. (2005). Role of c-Jun NH2-terminal kinase in G-protein-coupled receptor agonist-induced cardiac plasminogen activator inhibitor-1 expression. J Mol Cell Cardiol 38: 583-592.
38. Panchapakesan U, Sumual S, Pollock CA, Chen X (2005). PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 289: F1153-F1158.
39. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE et al. (1998). Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab 83: 2830-2835.
40. Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X (2006). Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton) 11: 516-523.
41. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007). TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74: 196-206.
42. Su JL, Winegar DA, Wisely GB, Sigel CS, Hull-Ryde EA (1999). Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro. Hybridoma 18: 273-280.
43. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I et al. (2000). Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 87: 596-602.
44. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M et al. (2004). Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 164: 449-456.
45. Verrecchia F, Mauviel A (2002). Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118: 211-215.
46. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B et al. (2002). Ligands of the peroxisome proliferatoractivated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16: 1027-1040.
47. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB et al. (2005). Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 25: 365-371.
48. Yamamoto K, Saito H (1998). A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 68: 371-385.
49. Ye P, Sheng L, Zhang C, Liu Y (2006). Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci 9: 365-375.
50. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA (2005). Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 16: 638-645.
51. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM (2006). PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 350: 385-391.
52. Zirlik A, Leugers A, Lohrmann J, Ernst S, Sobel BE, Bode C et al. (2004). Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 91: 674-682.